CN116056760A - {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途 - Google Patents

{2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途 Download PDF

Info

Publication number
CN116056760A
CN116056760A CN202180056233.1A CN202180056233A CN116056760A CN 116056760 A CN116056760 A CN 116056760A CN 202180056233 A CN202180056233 A CN 202180056233A CN 116056760 A CN116056760 A CN 116056760A
Authority
CN
China
Prior art keywords
crystalline form
peaks
xrpd pattern
cyclohexyl
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180056233.1A
Other languages
English (en)
Chinese (zh)
Inventor
滕菁
曹亦铮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
vTv Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by vTv Therapeutics LLC filed Critical vTv Therapeutics LLC
Priority to CN202511373032.0A priority Critical patent/CN121202809A/zh
Publication of CN116056760A publication Critical patent/CN116056760A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN202180056233.1A 2020-06-08 2021-06-07 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途 Pending CN116056760A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511373032.0A CN121202809A (zh) 2020-06-08 2021-06-07 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035994P 2020-06-08 2020-06-08
US63/035,994 2020-06-08
PCT/US2021/036082 WO2021252309A1 (en) 2020-06-08 2021-06-07 Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511373032.0A Division CN121202809A (zh) 2020-06-08 2021-06-07 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途

Publications (1)

Publication Number Publication Date
CN116056760A true CN116056760A (zh) 2023-05-02

Family

ID=78846441

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180056233.1A Pending CN116056760A (zh) 2020-06-08 2021-06-07 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途
CN202511373032.0A Pending CN121202809A (zh) 2020-06-08 2021-06-07 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511373032.0A Pending CN121202809A (zh) 2020-06-08 2021-06-07 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途

Country Status (8)

Country Link
EP (1) EP4161639A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023530785A (cg-RX-API-DMAC7.html)
KR (1) KR20230048501A (cg-RX-API-DMAC7.html)
CN (2) CN116056760A (cg-RX-API-DMAC7.html)
AU (1) AU2021289591A1 (cg-RX-API-DMAC7.html)
CA (1) CA3181665A1 (cg-RX-API-DMAC7.html)
MX (2) MX2022015524A (cg-RX-API-DMAC7.html)
WO (1) WO2021252309A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
US12479808B2 (en) 2020-06-08 2025-11-25 Vtv Therapeutics Llc Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102906077A (zh) * 2010-05-26 2013-01-30 转化技术制药公司 二甲双胍与葡萄糖激酶激活剂的联合使用以及包含二甲双胍和葡萄糖激酶激活剂的组合物
CN105188676A (zh) * 2013-03-04 2015-12-23 Vtv治疗有限责任公司 包括葡糖激酶活化剂的固体组合物及其制备和使用方法
US20160015638A1 (en) * 2013-03-04 2016-01-21 Vtv Therapeutics Llc Stable glucokinase activator compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0506662B8 (pt) * 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
IN2014DN09554A (cg-RX-API-DMAC7.html) * 2012-05-17 2015-07-17 Transtech Pharma Llc
DK3556354T3 (da) * 2016-12-15 2025-08-04 Hua Medicine Shanghai Ltd Oral fremstilling af en glucokinaseaktivator og fremgangsmåde til fremstilling deraf

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102906077A (zh) * 2010-05-26 2013-01-30 转化技术制药公司 二甲双胍与葡萄糖激酶激活剂的联合使用以及包含二甲双胍和葡萄糖激酶激活剂的组合物
CN105188676A (zh) * 2013-03-04 2015-12-23 Vtv治疗有限责任公司 包括葡糖激酶活化剂的固体组合物及其制备和使用方法
US20160015638A1 (en) * 2013-03-04 2016-01-21 Vtv Therapeutics Llc Stable glucokinase activator compositions

Also Published As

Publication number Publication date
MX2026000786A (es) 2026-03-02
JP2026108667A (ja) 2026-06-30
US20230219910A1 (en) 2023-07-13
EP4161639A4 (en) 2024-01-17
AU2021289591A1 (en) 2023-01-19
MX2022015524A (es) 2023-03-22
CA3181665A1 (en) 2021-12-16
WO2021252309A1 (en) 2021-12-16
JP2023530785A (ja) 2023-07-19
EP4161639A1 (en) 2023-04-12
CN121202809A (zh) 2025-12-26
KR20230048501A (ko) 2023-04-11

Similar Documents

Publication Publication Date Title
CN110922407B (zh) 苯甲酰氨基吡啶衍生物的晶型及其用途
CN112638904A (zh) 2-(3,5-二氯-4-((5-异丙基-6-氧代-1,6-二氢哒嗪-3-基)氧基)苯基)-3,5-二氧代-2,3,4,5-四氢-1,2,4-三嗪-6-腈的固体形式
CN121202809A (zh) {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途
EP4010322B1 (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
JP5566907B2 (ja) N−(tert−ブトキシカルボニル)−3−メチル−l−バリル−(4r)−4−((7−クロロ−4−メトキシ−1−イソキノリニル)オキシ)−n−((1r,2s)−1−((シクロプロピルスルホニル)カルバモイル)−2−ビニルシクロプロピル)−l−プロリンアミドの結晶フォーム
CN116194442A (zh) {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的盐或共晶体及其用途
TW202333676A (zh) 吡唑並〔3,4-d〕嘧啶化合物之固體形式
CN118894894A (zh) 新生霉素类似物与脯氨酸的共晶体形式
HK40131995A (en) Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and uses thereof
US12030886B2 (en) Form of ponatinib
US20220251091A1 (en) Amorphous umbralisib monotosylate
KR20220012222A (ko) 방향족 화합물의 고체 형태 및 그 제조 방법
HK40119275A (en) Co-crystal forms of a novobiocin analog and proline
HK40112450A (en) Solid forms of pyrazolo[3,4-d]pyrimidine compounds
US20210032235A1 (en) Crystalline forms of dasatinib
US20210246159A1 (en) Novel form of bardoxolone methyl
US20220298158A1 (en) Polymorph of venetoclax and method for preparing the polymorph
EA052651B1 (ru) ТВЕРДЫЕ ФОРМЫ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫХ СОЕДИНЕНИЙ
HK40074778A (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
HK40074778B (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
CA3057716A1 (en) Novel forms of afatinib dimaleate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20230502